Suraksha Diagnostic Ltd Q3 FY25 Results & Concall Highlights: Revenue, Margins & Order Book
Published 3 Aug 2026 | Healthcare Services | Market Cap: ₹1.6K Cr
Targeting a revenue growth of 15% annually, as confirmed by management. Suraksha Diagnostic aims for a revenue growth target of 15% annually as reaffirmed by management.
From Suraksha Diagnostic Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Price
₹326
Market Cap
₹1.6K Cr
P/E Ratio
44.4
How does Suraksha Diagnostic Ltd rank in Healthcare Services?
Compare Suraksha Diagnostic Ltd against every Healthcare Services company this quarter on revenue, margins and earnings-call signals.
Suraksha Diagnostic Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹81 Cr, net profit ₹6 Cr.
Full financials →📊 Revenue & Sales Performance
- →Targeting a revenue growth of 15% annually, as confirmed by management.
- →Volume mix expected to remain stable with around 75% pathology and 25% radiology tests.
- →Continued organic expansion with plans to open 12-15 new centers every year for the next 3 years, aiming to reach 100 centers.
- →Focus on increasing the number of polyclinic chambers and associated doctor fees, showing improved conversion rates.
- →Stable revenue mix between pathology (around 54-56%) and radiology (44-45%), consistent over the last 2-3 years.
- →Growth supported by technology investments and operational efficiencies.
- →Green shoots observed in accommodating hospital chains' super specialists in polyclinics.
- →Expect volume growth from specialized pathology tests, currently at ~45%, with an aim to increase their share over the coming years.
📈 Profitability & Margins
- →Suraksha Diagnostic aims for a revenue growth target of 15% annually as reaffirmed by management.
- →The company plans a 100 basis points (1%) expansion in EBITDA margin each year.
- →EBITDA margins for existing centers are targeted around 40-41% over the next 2-3 years.
- →New centers, including small and medium ones, typically become EBITDA positive within 3-4 months; larger centers take 6-7 months.
- →The company is focusing on opening 12-15 new centers annually over the next 3 years to reach 100 centers.
- →Operating leverage and cost control measures contributed to a 16.7% YoY EBITDA increase in Q3 FY25 and 22.4% over 9 months FY25.
- →Profit after tax grew by approximately 31.9% YoY in Q3 FY25.
- →Guidance explicitly stays on track despite short-term impacts like doctor strikes and seasonality.
🏗️ Capital Expenditure Plans
- →Suraksha Diagnostic Limited has budgeted a capital expenditure (capex) of around INR 70 crores per year.
- →Of this capex, 5% to 7% is allocated towards maintenance, with the remainder directed towards expansion.
- →The company plans to add 12 to 15 new centers annually over the next three years, targeting a total of 100 centers within that period.
- →Future capex plans do not include potential mergers and acquisitions (M&A); acquisitions will be additional to the INR 70 crore capex.
- →The company is actively exploring strategic partnerships and acquisitions that align with their values to expand geographic footprint and service offerings.
- →Investments include technology upgrades, such as adding new technologies to reference labs (e.g., microarray, standard sequencing) to strengthen genomics capabilities.
- →Plans also include opening polyclinic chambers and expansion in PPP models as part of strategic growth.
💰 Fundraising & Capital Structure
- →There is no direct mention of any current or planned fundraising through debt or equity in the provided transcript.
- →The company is focused on organic expansion by adding 12 to 15 new centers annually and is exploring inorganic growth through strategic partnerships and acquisitions.
- →Capex guidance is around INR 70 crores per year for expansion and maintenance; this does not include acquisitions.
- →The company is actively looking for acquisitions and partnerships but no specifics on funding methods (debt or equity) for these are mentioned.
- →Lease liabilities are clarified under accounting standards and are not considered traditional debt.
- →Overall, no explicit plans for fundraising through debt or equity were stated in this conference call.
📋 Order Book & Pipeline
Key Metrics
Frequently Asked Questions
What were Suraksha Diagnostic Ltd Q3 FY25 results?
Targeting a revenue growth of 15% annually, as confirmed by management. Suraksha Diagnostic aims for a revenue growth target of 15% annually as reaffirmed by management.
What is Suraksha Diagnostic Ltd share price analysis?
Suraksha Diagnostic Ltd currently shows a neutral. The stock trades at a P/E of 44.4 with a market cap of ₹1,588 Cr. Investors should review the full earnings analysis for detailed insights.
Is Suraksha Diagnostic Ltd planning capital expenditure?
Suraksha Diagnostic Limited has budgeted a capital expenditure (capex) of around INR 70 crores per year.
Keep Suraksha Diagnostic Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.